Drugs / pipobroman
pipobroman
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VERCYTE | — | 1966-07-01 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02038036 Background | Mar 2014 → Sep 2015 | acquired polycythemia vera | Novartis Pharmaceuticals | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pipobroman | “Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation.” NCT02038036 ↗ |
| Known as | A-8103 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1585 ↗ |
| Known as | NSC-25154 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1585 ↗ |
| Known as | Vercyte | ChEMBL registry synonym — accepted as the source's own label CHEMBL1585 ↗ |
| Modality | Small molecule | — CHEMBL1585 ↗ |